Our blood consists of many cell types that develop through different stages from a precursor type—the blood stem cell. An ...

EVM14 is the first messenger RNA (mRNA) therapeutic vaccine developed internally by the company to gain this approval. Its ...

These immune responses mobilized both antibody- and cell-mediated immunity and persisted until week 48, 6 months after the last boost (Y. Levy et al., EClinicalMedicine, 2024). The long-term follow-up ...

Our immune system works to fight infections immediately, but also maintain long-term immunity. Two waves of protection help neutralize and eliminate diseas | Immunology ...

While most current research and immunotherapeutic strategies focus on other immune cells ... the role of CTLs in IL-3-mediated tumor control. To further explore the effect of IL-3 on CTLs, the ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

FRANKFURT. Every second, an adult generates around five million new blood cells to replace aging or dying ones, making the blood system a highly ...

Every second, an adult generates around five million new blood cells to replace aging or dying ones, making the blood system a highly regenerative ...